Invivyd, Inc. Form 8-K Summary
Business Context and Reporting Period
Invivyd, Inc. filed a Form 8-K dated October 20, 2022, with the report signed and furnished on October 24, 2022. The filing concerns changes to the company’s board of directors and does not report quarterly or annual financial results.
Financial Metrics and Capitalization
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics. It also does not disclose a financing, acquisition, or change to the company’s capital structure.
Material Changes
- Redonda Miller, M.D., M.B.A. resigned from the Board and all committees effective October 20, 2022.
- The filing states that Dr. Miller’s resignation was not due to any disagreement with the company regarding operations, policies, or practices.
- Christine Lindenboom was appointed as a Class II director effective October 20, 2022, with a term expiring at the 2023 annual meeting of stockholders.
- Ms. Lindenboom was also appointed to the Nominating and Corporate Governance Committee.
Compensation, Outlook, and Risks
- Ms. Lindenboom will receive the standard non-employee director compensation, including an annual Board retainer of $40,000 and an additional annual Nominating Committee retainer of $4,000.
- She received a nonqualified option for 150,000 common shares. The option vests over three years, is exercisable for 10 years, and has an exercise price equal to the closing sales price of the common stock on Nasdaq on October 20, 2022. The filing does not state the resulting per-share exercise price.
- The option is subject to continued service and the company’s 2021 Equity Incentive Plan, as amended.
- The company entered into its standard director indemnification agreement with Ms. Lindenboom, which may require indemnification for certain expenses, judgments, fines, and settlement amounts arising from her service.
- The filing discloses no reportable related-party relationships or arrangements involving Ms. Lindenboom and no specific business outlook or guidance.
Investor Verification Points
- Verify the final exercise price and accounting treatment of the 150,000-share option grant.
- Review the October 24, 2022 press release filed as Exhibit 99.1 for additional commentary on the Board changes.
- Confirm the resulting Board and committee composition following Dr. Miller’s resignation and Ms. Lindenboom’s appointment.
- Consult subsequent filings for any changes to director compensation, committee assignments, or the company’s financial position.